Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xencor has signed an agreement to exclusively license technology developed at the University of Cambridge that enables the creation of monoclonal antibodies with greatly enhanced potency.
Subscribe to our email newsletter
The technology includes specific Fc (antibody constant region) variants that complement Xencor’s proprietary suite of XmAb engineered Fc domains, which are designed to enhance the therapeutic properties of monoclonal antibodies.
Xencor’s XmAb antibody Fc domains can be inserted into antibody candidates against any target antigen, and may enhance certain functions of the antibody including its tumor cell killing capacity, duration of half-life and structural stability.
“Our strategy is to create potent antibody therapeutics by exploiting our suite of Fc variants that maximally enhance Fc-mediated effector function and offer a very broad range of therapeutic properties. This license further bolsters our leading proprietary position,” said Dr Bassil Dahiyat, president and CEO of Xencor.